Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Takeda bids adieu to Uloric
Takeda bids adieu to Uloric
Read also
From Patent to Patient
From Patent to Patient: FDA Policy Ideas to Protect and Speed Medical Innovation
Genmab
Genmab to acquire Merus shares for $8bn
Climb Bio
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Mytesi Seeks FDA
Mytesi Seeks FDA Orphan Drug Designation in Breast Cancer Diarrhea
